{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:02:20Z","timestamp":1791226940561,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T00:00:00Z","timestamp":1257379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T00:00:00Z","timestamp":1257379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1038\/leu.2009.228","type":"journal-article","created":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T14:58:47Z","timestamp":1257433127000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells"],"prefix":"10.1038","volume":"24","author":[{"given":"U","family":"Rix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L L","family":"Remsing Rix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Terker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N V","family":"Fernbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Hantschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Planyavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F P","family":"Breitwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Colinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K L","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J H","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Superti-Furga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,5]]},"reference":[{"key":"BFleu2009228_CR1","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K et al. NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948\u20133954.","journal-title":"Blood"},{"key":"BFleu2009228_CR2","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/djn188","volume":"100","author":"J Wu","year":"2008","unstructured":"Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008; 100: 926\u2013939.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2009228_CR3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690\u2013698.","journal-title":"Blood"},{"key":"BFleu2009228_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/nm1127","volume":"10","author":"A Ptasznik","year":"2004","unstructured":"Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM . Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004; 10: 1187\u20131189.","journal-title":"Nat Med"},{"key":"BFleu2009228_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/j.1349-7006.2007.00516.x","volume":"98","author":"J Pan","year":"2007","unstructured":"Pan J, Quintas-Cardama A, Manshouri T, Cortes J, Kantarjian H, Verstovsek S . Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Sci 2007; 98: 1223\u20131225.","journal-title":"Cancer Sci"},{"key":"BFleu2009228_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2006-03-013250","volume":"109","author":"A Yokota","year":"2007","unstructured":"Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K et al. INNO-406, a novel BCR-ABL\/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007; 109: 306\u2013314.","journal-title":"Blood"},{"key":"BFleu2009228_CR7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25: 1035\u20131044.","journal-title":"Nat Biotechnol"},{"key":"BFleu2009228_CR8","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055\u20134063.","journal-title":"Blood"},{"key":"BFleu2009228_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"LL Remsing Rix","year":"2009","unstructured":"Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009; 23: 477\u2013485.","journal-title":"Leukemia"},{"key":"BFleu2009228_CR10","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531\u20132541.","journal-title":"N Engl J Med"},{"key":"BFleu2009228_CR11","doi-asserted-by":"publisher","first-page":"13283","DOI":"10.1073\/pnas.0702654104","volume":"104","author":"O Hantschel","year":"2007","unstructured":"Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104: 13283\u201313288.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2009228_CR12","first-page":"1731","volume":"47","author":"SA Maxwell","year":"1987","unstructured":"Maxwell SA, Kurzrock R, Parsons SJ, Talpaz M, Gallick GE, Kloetzer WS et al. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res 1987; 47: 1731\u20131739.","journal-title":"Cancer Res"},{"key":"BFleu2009228_CR13","doi-asserted-by":"publisher","first-page":"19298","DOI":"10.1074\/jbc.M413059200","volume":"280","author":"X Wang","year":"2005","unstructured":"Wang X, Mader MM, Toth JE, Yu X, Jin N, Campbell RM et al. Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J Biol Chem 2005; 280: 19298\u201319305.","journal-title":"J Biol Chem"},{"key":"BFleu2009228_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6807-9-7","volume":"9","author":"JA Winger","year":"2009","unstructured":"Winger JA, Hantschel O, Superti-Furga G, Kuriyan J . The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct Biol 2009; 9: 7.","journal-title":"BMC Struct Biol"},{"key":"BFleu2009228_CR15","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357\u20135364.","journal-title":"J Clin Oncol"},{"key":"BFleu2009228_CR16","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.bmcl.2007.03.002","volume":"17","author":"T Horio","year":"2007","unstructured":"Horio T, Hamasaki T, Inoue T, Wakayama T, Itou S, Naito H et al. Structural factors contributing to the Abl\/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorg Med Chem Lett 2007; 17: 2712\u20132717.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFleu2009228_CR17","first-page":"1297","volume":"2","author":"M Schirle","year":"2003","unstructured":"Schirle M, Heurtier M-A, Kuster B . Profiling core proteomes of human cell lines by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry. Mol Cell 2003; 2: 1297\u20131305.","journal-title":"Mol Cell"},{"key":"BFleu2009228_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1074\/mcp.M200035-MCP200","volume":"1","author":"DL Smith","year":"2002","unstructured":"Smith DL, Evans CA, Pierce A, Gaskell SJ, Whetton AD . Changes in the proteome associated with the action of Bcr-Abl tyrosine kinase are not related to transcriptional regulation. Mol Cell Proteomics 2002; 1: 876\u2013884.","journal-title":"Mol Cell Proteomics"},{"key":"BFleu2009228_CR19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1080\/10428190801942360","volume":"49","author":"C Villalva","year":"2008","unstructured":"Villalva C, Sorel N, Bonnet ML, Guilhot J, Mayeur-Rousse C, Guilhot F et al. Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia. Leuk Lymphoma 2008; 49: 984\u2013988.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2009228_CR20","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1038\/onc.2008.209","volume":"27","author":"X Leng","year":"2008","unstructured":"Leng X, Lin H, Ding T, Wang Y, Wu Y, Klumpp S et al. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene 2008; 27: 6110\u20136119.","journal-title":"Oncogene"},{"key":"BFleu2009228_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","volume":"599","author":"E Day","year":"2008","unstructured":"Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008; 599: 44\u201353.","journal-title":"Eur J Pharmacol"},{"key":"BFleu2009228_CR22","first-page":"2275","volume":"55","author":"T Skorski","year":"1995","unstructured":"Skorski T, Nieborowska-Skorska M, Szczylik C, Kanakaraj P, Perrotti D, Zon G et al. C-RAF-1 serine\/threonine kinase is required in BCR\/ABL-dependent and normal hematopoiesis. Cancer Res 1995; 55: 2275\u20132278.","journal-title":"Cancer Res"},{"key":"BFleu2009228_CR23","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1053\/j.gastro.2006.09.017","volume":"131","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006; 131: 1734\u20131742.","journal-title":"Gastroenterology"},{"key":"BFleu2009228_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cell.2008.03.011","volume":"133","author":"EB Pasquale","year":"2008","unstructured":"Pasquale EB . Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133: 38\u201352.","journal-title":"Cell"},{"key":"BFleu2009228_CR25","doi-asserted-by":"publisher","first-page":"re2","DOI":"10.1126\/stke.115re2","volume":"1","author":"M Lackmann","year":"2008","unstructured":"Lackmann M, Boyd AW . Eph, a protein family coming of age: more confusion, insight, or complexity? Sci Signal 2008; 1: re2.","journal-title":"Sci Signal"},{"key":"BFleu2009228_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1568009053765780","volume":"5","author":"RC Ireton","year":"2005","unstructured":"Ireton RC, Chen J . EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 2005; 5: 149\u2013157.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFleu2009228_CR27","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/j.1462-5822.2008.01139.x","volume":"10","author":"DM Jandhyala","year":"2008","unstructured":"Jandhyala DM, Ahluwalia A, Obrig T, Thorpe CM . ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell Microbiol 2008; 10: 1468\u20131477.","journal-title":"Cell Microbiol"},{"key":"BFleu2009228_CR28","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.bbrc.2004.09.156","volume":"324","author":"CY Huang","year":"2004","unstructured":"Huang CY, Chueh PJ, Tseng CT, Liu KY, Tsai HY, Kuo WW et al. ZAK re-programs atrial natriuretic factor expression and induces hypertrophic growth in H9c2 cardiomyoblast cells. Biochem Biophys Res Commun 2004; 324: 973\u2013980.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu2009228_CR29","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1158\/0008-5472.CAN-04-0201","volume":"64","author":"YY Cho","year":"2004","unstructured":"Cho YY, Bode AM, Mizuno H, Choi BY, Choi HS, Dong Z . A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase alpha in neoplastic cell transformation and tumor development. Cancer Res 2004; 64: 3855\u20133864.","journal-title":"Cancer Res"},{"key":"BFleu2009228_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4137\/117739010700200008","volume":"2","author":"T Niwa","year":"2007","unstructured":"Niwa T, Asaki T, Kimura S . NS-187 (INNO-406), a Bcr-Abl\/Lyn dual tyrosine kinase inhibitor. Anal Chem Insights 2007; 2: 93\u2013106.","journal-title":"Anal Chem Insights"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2009228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2009228","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2009228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:14:48Z","timestamp":1648728888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2009228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,5]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["BFleu2009228"],"URL":"https:\/\/doi.org\/10.1038\/leu.2009.228","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,5]]},"assertion":[{"value":"20 April 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}